Physician profile
Jonathan Chorney
NPI 1235541269
$9,920.02
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2020: $1,683 · 2021: $3,121 · 2022: $2,403 · 2023: $939 · 2024: $43.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,323.53 | 2020-2023 | Vraylar, Ubrelvy, Linzess |
| Biohaven Pharmaceuticals, INC. | $1,308.16 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $970.18 | 2019-2023 | Trulance, Xifaxan |
| Amgen INC. | $765.47 | 2019-2023 | Otezla, Repatha |
| Daiichi Sankyo INC. | $565.21 | 2019-2022 | |
| Abbott Laboratories | $531.34 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $490.41 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $446.82 | 2019-2023 | Fasenra, Farxiga, Breztri |
| Novo Nordisk INC | $330.85 | 2019-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $224.93 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $209.47 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $206.06 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $167.50 | 2019-2022 | |
| Amarin Pharma, INC. | $166.16 | 2020-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Chorney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.